ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 4.1 | 7.2 | 6.7 |
| Other income | 0.0 | 0.1 | 0.0 |
| Total income | 4.2 | 7.3 | 6.7 |
| Profit before exceptional items & tax | -1.8 | -1.4 | -7.2 |
| Exceptional items | 4.2 | -0.1 | 0.0 |
| Profit before tax | 2.4 | -1.5 | -7.2 |
| Net profit | 1.9 | -1.1 | 5.3 |
| Operating margin | 57.1% | -20.5% | -107.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -64.20% |
|---|---|
| Revenue, year on year | -38.80% |
| Operating profit, year on year | +75.00% |
| Operating profit, quarter on quarter | -20.00% |
BSE results filing, NSE: PHARMAID. Figures extracted from the filing.
Pharmaids Pharmaceuticals Ltd: key numbers
- Share price
- ₹29.17
- Market cap
- ₹102.9 Cr
- Revenue (annual)
- ₹27.88 Cr
- Net profit (annual)
- ₹-11.72 Cr
- P/E (TTM)
- -24.6×Sector 43.8×
- Promoter holding
- 32.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Pharmaids Pharmaceuticals Ltd
All →Pharmaids Pharmaceuticals Q2 FY27 Results: Net Loss of ₹1.8 Cr, Loss Narrows
Pharmaids Pharmaceuticals Ltd reported revenue from operations of ₹4.3 Cr (-50.0% YoY) and a net loss of ₹1.8 Cr for Q2 FY27.
- Key figure
- Net loss ₹1.8 Cr
Pharmaids Pharmaceuticals Board Meeting Date
Pharmaids Pharmaceuticals Ltd intimated BSE of a board meeting on 11 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The notice contains no figures, and the trading window stays closed from 1 October 2026.
Pharmaids Pharmaceuticals Other Announcement
Pharmaids Pharmaceuticals Limited filed its quarterly Regulation 74(5) compliance certificate from its Registrar and Share Transfer Agent confirming the dematerialization of shares.
Pharmaids Pharmaceuticals Legal & Regulatory
Pharmaids Pharmaceuticals filed legal complaints against Anugraha Chemicals for dishonoured cheques totalling ₹2.63 Crore in outstanding dues from a disinvestment agreement.
- Value
- ₹2.63 Cr
Pharmaids Pharmaceuticals Annual General Meeting
Pharmaids Pharmaceuticals held its 37th AGM via video conference on 11 Sept 2026. Four resolutions including adoption of FY26 financials and related-party-transaction approvals were tabled.
Pharmaids Pharmaceuticals Promoter Buying (Off-Market)
KMP Prasanna Subramanya Bhat acquired 17,291 shares of Pharmaids Pharmaceuticals Ltd via a gift from an immediate relative. This off-market transfer is an insider disclosure.
- Promoter stake change
- +0.04%